Item 2.02 Results of Operations and Financial Condition.

On January 6, 2022, HTG Molecular Diagnostics, Inc. issued a press release announcing certain preliminary financial results as of and for the full year ended December 31, 2021. A copy of this press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the attached exhibit 99.1 are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Included as Exhibit 99.2 to this Current Report on Form 8-K is our corporate presentation, dated January 2022, which is incorporated by reference. We intend to utilize this presentation and its contents in various meetings with securities analysts, investors and others in connection with the Annual LifeSci Partners Corporate Access Event, the H.C. Wainwright Bioconnect Conference and the Annual J.P. Morgan Healthcare Conference, commencing on January 6, 2022.

The information in this Item 7.01 and the attached exhibit 99.2 are being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits



Exhibit
  No.     Description

99.1        Press release of HTG Molecular Diagnostics, Inc. dated January 6, 2022

99.2        Corporate Presentation

104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses